What Is Titration?
Category: Dosing
The process of gradually increasing a medication dose over time. Essential for GLP-1 agonists to minimize gastrointestinal side effects. Typically involves increasing the dose every 4 weeks.
Detailed Explanation
Titration in peptide dosing refers to the practice of starting at a low dose and gradually increasing it over time to reach the target therapeutic dose. This approach allows the body to adapt to the medication and reduces the incidence and severity of side effects. Titration is particularly important for GLP-1 agonists like semaglutide and tirzepatide, where rapid dose escalation can cause severe gastrointestinal symptoms.
Practical Context
For semaglutide, a typical titration schedule starts at 250mcg per week, increasing by 250mcg every 4 weeks until reaching the target dose. For tirzepatide, start at 2.5mg per week, increasing by 2.5mg every 4 weeks. If side effects are severe at any dose level, remain at that dose for an additional 4 weeks before attempting to increase again. Never skip titration steps, even if side effects are minimal - gradual escalation is always recommended.
Frequently Asked Questions
What happens if I skip the titration phase?
Skipping titration and starting at a full dose, especially with GLP-1 agonists, can cause severe nausea, vomiting, diarrhea, and other gastrointestinal symptoms. It does not speed up results but significantly increases discomfort.
Related Peptides
- Semaglutide - A GLP-1 receptor agonist used for weight management and blood sugar control. (Dosage | Calculator)
- Tirzepatide - A dual GIP and GLP-1 receptor agonist for weight management. (Dosage | Calculator)
Related Terms
- Dose-Response Curve - The relationship between the amount of peptide administered and the magnitude of its effect. Higher doses don't always mean better results and can sometimes cause diminishing returns.
- Semaglutide - A GLP-1 receptor agonist used for weight management and type 2 diabetes. The active ingredient in brand-name medications Ozempic and Wegovy. Administered once weekly.
- Tirzepatide - A dual GLP-1/GIP receptor agonist for weight management and type 2 diabetes. Clinical trials showed up to 22.5% body weight reduction. Brand names include Mounjaro and Zepbound.
- GLP-1 (Glucagon-Like Peptide-1) - A gut hormone that regulates appetite, blood sugar, and gastric emptying. GLP-1 agonists like semaglutide and tirzepatide mimic this hormone for weight management.